APO Research
Talk to an analyst

APO RESEARCH · REPORT

Malignant Ascites Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Malignant Ascites Treatment Market Outlook and Growth Opportunities 2026

29 December 2025196 pages

Choose your research edition.

Industry ResearchMalignant Ascites Treatment Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Malignant Ascites Treatment Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Malignant Ascites Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Malignant Ascites Treatment Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Malignant Ascites Treatment Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Malignant Ascites Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Malignant Ascites Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Malignant Ascites Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Malignant Ascites Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Malignant Ascites Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Malignant Ascites Treatment market include BD, Pfizer, B. Braun, The Surgical Company Group, Sequana Medical, PharmaCyte Biotech, Pfm Medical Ag, Merit Medical Systems and Medtronic, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Malignant Ascites Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Malignant Ascites Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Malignant Ascites Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Malignant Ascites Treatment market.

Malignant Ascites Treatment Segment by Company

BD

Pfizer

B. Braun

The Surgical Company Group

Sequana Medical

PharmaCyte Biotech

Pfm Medical Ag

Merit Medical Systems

Medtronic

GI Supply (Laborie Medical Technologies)

CMP Pharma

Clover Biopharmaceuticals

BioVie

Malignant Ascites Treatment Segment by Type

Surgical Treatment

Chemotherapy

Paracentesis

Others

Malignant Ascites Treatment Segment by Application

Homecare

Hospitals

Clinics

Others

Malignant Ascites Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Malignant Ascites Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Malignant Ascites Treatment key companies, revenue, market share, and recent developments.

3. To split the Malignant Ascites Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Malignant Ascites Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Malignant Ascites Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Malignant Ascites Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Malignant Ascites Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Malignant Ascites Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Malignant Ascites Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Malignant Ascites Treatment industry.

Chapter 3: Detailed analysis of Malignant Ascites Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Malignant Ascites Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Malignant Ascites Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Malignant Ascites Treatment Industry Trends Table 2. Malignant Ascites Treatment Industry Drivers Table 3. Malignant Ascites Treatment Industry Opportunities and Challenges Table 4. Malignant Ascites Treatment Industry Restraints Table 5. Global Malignant Ascites Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Malignant Ascites Treatment Revenue Share by Company (2021-2026) Table 7. Global Malignant Ascites Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Malignant Ascites Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Malignant Ascites Treatment Company, Product Type & Application Table 10. Global Malignant Ascites Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Malignant Ascites Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Surgical Treatment Table 15. Significant Companies of Chemotherapy Table 16. Significant Companies of Paracentesis Table 17. Significant Companies of Others Table 18. Global Malignant Ascites Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Malignant Ascites Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Malignant Ascites Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Malignant Ascites Treatment Sales Value Share by Type (2021-2026) Table 22. Global Malignant Ascites Treatment Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Homecare Table 24. Significant Companies of Hospitals Table 25. Significant Companies of Clinics Table 26. Significant Companies of Others Table 27. Global Malignant Ascites Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Malignant Ascites Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Malignant Ascites Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Malignant Ascites Treatment Sales Value Share by Application (2021-2026) Table 31. Global Malignant Ascites Treatment Sales Value Share by Application (2027-2032) Table 32. Global Malignant Ascites Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Malignant Ascites Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Malignant Ascites Treatment Sales Value Share by Region (2021-2026) Table 35. Global Malignant Ascites Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Malignant Ascites Treatment Sales Value Share by Region (2027-2032) Table 37. Global Malignant Ascites Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Malignant Ascites Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Malignant Ascites Treatment Sales Value Market Share by Country (2021-2026) Table 40. Global Malignant Ascites Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Malignant Ascites Treatment Sales Value Market Share by Country (2027-2032) Table 42. BD Company Information Table 43. BD Business Overview Table 44. BD Malignant Ascites Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. BD Malignant Ascites Treatment Product Portfolio Table 46. BD Recent Development Table 47. Pfizer Company Information Table 48. Pfizer Business Overview Table 49. Pfizer Malignant Ascites Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Pfizer Malignant Ascites Treatment Product Portfolio Table 51. Pfizer Recent Development Table 52. B. Braun Company Information Table 53. B. Braun Business Overview Table 54. B. Braun Malignant Ascites Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. B. Braun Malignant Ascites Treatment Product Portfolio Table 56. B. Braun Recent Development Table 57. The Surgical Company Group Company Information Table 58. The Surgical Company Group Business Overview Table 59. The Surgical Company Group Malignant Ascites Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. The Surgical Company Group Malignant Ascites Treatment Product Portfolio Table 61. The Surgical Company Group Recent Development Table 62. Sequana Medical Company Information Table 63. Sequana Medical Business Overview Table 64. Sequana Medical Malignant Ascites Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Sequana Medical Malignant Ascites Treatment Product Portfolio Table 66. Sequana Medical Recent Development Table 67. PharmaCyte Biotech Company Information Table 68. PharmaCyte Biotech Business Overview Table 69. PharmaCyte Biotech Malignant Ascites Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. PharmaCyte Biotech Malignant Ascites Treatment Product Portfolio Table 71. PharmaCyte Biotech Recent Development Table 72. Pfm Medical Ag Company Information Table 73. Pfm Medical Ag Business Overview Table 74. Pfm Medical Ag Malignant Ascites Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Pfm Medical Ag Malignant Ascites Treatment Product Portfolio Table 76. Pfm Medical Ag Recent Development Table 77. Merit Medical Systems Company Information Table 78. Merit Medical Systems Business Overview Table 79. Merit Medical Systems Malignant Ascites Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Merit Medical Systems Malignant Ascites Treatment Product Portfolio Table 81. Merit Medical Systems Recent Development Table 82. Medtronic Company Information Table 83. Medtronic Business Overview Table 84. Medtronic Malignant Ascites Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Medtronic Malignant Ascites Treatment Product Portfolio Table 86. Medtronic Recent Development Table 87. GI Supply (Laborie Medical Technologies) Company Information Table 88. GI Supply (Laborie Medical Technologies) Business Overview Table 89. GI Supply (Laborie Medical Technologies) Malignant Ascites Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. GI Supply (Laborie Medical Technologies) Malignant Ascites Treatment Product Portfolio Table 91. GI Supply (Laborie Medical Technologies) Recent Development Table 92. CMP Pharma Company Information Table 93. CMP Pharma Business Overview Table 94. CMP Pharma Malignant Ascites Treatment Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. CMP Pharma Malignant Ascites Treatment Product Portfolio Table 96. CMP Pharma Recent Development Table 97. Clover Biopharmaceuticals Company Information Table 98. Clover Biopharmaceuticals Business Overview Table 99. Clover Biopharmaceuticals Malignant Ascites Treatment Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Clover Biopharmaceuticals Malignant Ascites Treatment Product Portfolio Table 101. Clover Biopharmaceuticals Recent Development Table 102. BioVie Company Information Table 103. BioVie Business Overview Table 104. BioVie Malignant Ascites Treatment Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. BioVie Malignant Ascites Treatment Product Portfolio Table 106. BioVie Recent Development Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Malignant Ascites Treatment Product Image Figure 2. Global Malignant Ascites Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Malignant Ascites Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Malignant Ascites Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Surgical Treatment Image Figure 8. Chemotherapy Image Figure 9. Paracentesis Image Figure 10. Others Image Figure 11. Global Malignant Ascites Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Malignant Ascites Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Malignant Ascites Treatment Sales Value Share by Type (2021-2032) Figure 14. Homecare Image Figure 15. Hospitals Image Figure 16. Clinics Image Figure 17. Others Image Figure 18. Global Malignant Ascites Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Malignant Ascites Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Malignant Ascites Treatment Sales Value Share by Application (2021-2032) Figure 21. Global Malignant Ascites Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Malignant Ascites Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Malignant Ascites Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. North America Malignant Ascites Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Malignant Ascites Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Malignant Ascites Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Malignant Ascites Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Malignant Ascites Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Malignant Ascites Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. South America Malignant Ascites Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Malignant Ascites Treatment Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Malignant Ascites Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Malignant Ascites Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Surgical Treatment
  • Chemotherapy
  • Paracentesis
  • Others
Applications
  • Homecare
  • Hospitals
  • Clinics
  • Others
Companies covered
  • BD
  • Pfizer
  • B. Braun
  • The Surgical Company Group
  • Sequana Medical
  • PharmaCyte Biotech
  • Pfm Medical Ag
  • Merit Medical Systems
  • Medtronic
  • GI Supply (Laborie Medical Technologies)
  • CMP Pharma
  • Clover Biopharmaceuticals
  • BioVie

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Malignant Ascites Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Malignant Ascites Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Malignant Ascites Treatment Market Dynamics
  1. 2.1 Malignant Ascites Treatment Industry Trends
  2. 2.2 Malignant Ascites Treatment Industry Drivers
  3. 2.3 Malignant Ascites Treatment Industry Opportunities and Challenges
  4. 2.4 Malignant Ascites Treatment Industry Restraints
3 Malignant Ascites Treatment Market by Company
  1. 3.1 Global Malignant Ascites Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Malignant Ascites Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Malignant Ascites Treatment Company Ranking (2024-2026)
  4. 3.4 Global Malignant Ascites Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Malignant Ascites Treatment Company Product Type and Application
  6. 3.6 Global Malignant Ascites Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Malignant Ascites Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Malignant Ascites Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Malignant Ascites Treatment Market by Type
  1. 4.1 Malignant Ascites Treatment Type Introduction
  2. 4.1.1 Surgical Treatment
  3. 4.1.2 Chemotherapy
  4. 4.1.3 Paracentesis
  5. 4.1.4 Others
  6. 4.2 Global Malignant Ascites Treatment Sales Value by Type
  7. 4.2.1 Global Malignant Ascites Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Malignant Ascites Treatment Sales Value by Type (2021-2032)
  9. 4.2.3 Global Malignant Ascites Treatment Sales Value Share by Type (2021-2032)
5 Malignant Ascites Treatment Market by Application
  1. 5.1 Malignant Ascites Treatment Application Introduction
  2. 5.1.1 Homecare
  3. 5.1.2 Hospitals
  4. 5.1.3 Clinics
  5. 5.1.4 Others
  6. 5.2 Global Malignant Ascites Treatment Sales Value by Application
  7. 5.2.1 Global Malignant Ascites Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Malignant Ascites Treatment Sales Value by Application (2021-2032)
  9. 5.2.3 Global Malignant Ascites Treatment Sales Value Share by Application (2021-2032)
6 Malignant Ascites Treatment Regional Value Analysis
  1. 6.1 Global Malignant Ascites Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Malignant Ascites Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Malignant Ascites Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Malignant Ascites Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Malignant Ascites Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Malignant Ascites Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Malignant Ascites Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Malignant Ascites Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Malignant Ascites Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Malignant Ascites Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Malignant Ascites Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Malignant Ascites Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Malignant Ascites Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Malignant Ascites Treatment Sales Value Share by Country, 2025 VS 2032
7 Malignant Ascites Treatment Country-level Value Analysis
  1. 7.1 Global Malignant Ascites Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Malignant Ascites Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Malignant Ascites Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Malignant Ascites Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Malignant Ascites Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Malignant Ascites Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Malignant Ascites Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 BD
  2. 8.1.1 BD Company Information
  3. 8.1.2 BD Business Overview
  4. 8.1.3 BD Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 BD Malignant Ascites Treatment Product Portfolio
  6. 8.1.5 BD Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Malignant Ascites Treatment Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 B. Braun
  14. 8.3.1 B. Braun Company Information
  15. 8.3.2 B. Braun Business Overview
  16. 8.3.3 B. Braun Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 B. Braun Malignant Ascites Treatment Product Portfolio
  18. 8.3.5 B. Braun Recent Developments
  19. 8.4 The Surgical Company Group
  20. 8.4.1 The Surgical Company Group Company Information
  21. 8.4.2 The Surgical Company Group Business Overview
  22. 8.4.3 The Surgical Company Group Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 The Surgical Company Group Malignant Ascites Treatment Product Portfolio
  24. 8.4.5 The Surgical Company Group Recent Developments
  25. 8.5 Sequana Medical
  26. 8.5.1 Sequana Medical Company Information
  27. 8.5.2 Sequana Medical Business Overview
  28. 8.5.3 Sequana Medical Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sequana Medical Malignant Ascites Treatment Product Portfolio
  30. 8.5.5 Sequana Medical Recent Developments
  31. 8.6 PharmaCyte Biotech
  32. 8.6.1 PharmaCyte Biotech Company Information
  33. 8.6.2 PharmaCyte Biotech Business Overview
  34. 8.6.3 PharmaCyte Biotech Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 PharmaCyte Biotech Malignant Ascites Treatment Product Portfolio
  36. 8.6.5 PharmaCyte Biotech Recent Developments
  37. 8.7 Pfm Medical Ag
  38. 8.7.1 Pfm Medical Ag Company Information
  39. 8.7.2 Pfm Medical Ag Business Overview
  40. 8.7.3 Pfm Medical Ag Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfm Medical Ag Malignant Ascites Treatment Product Portfolio
  42. 8.7.5 Pfm Medical Ag Recent Developments
  43. 8.8 Merit Medical Systems
  44. 8.8.1 Merit Medical Systems Company Information
  45. 8.8.2 Merit Medical Systems Business Overview
  46. 8.8.3 Merit Medical Systems Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Merit Medical Systems Malignant Ascites Treatment Product Portfolio
  48. 8.8.5 Merit Medical Systems Recent Developments
  49. 8.9 Medtronic
  50. 8.9.1 Medtronic Company Information
  51. 8.9.2 Medtronic Business Overview
  52. 8.9.3 Medtronic Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Medtronic Malignant Ascites Treatment Product Portfolio
  54. 8.9.5 Medtronic Recent Developments
  55. 8.10 GI Supply (Laborie Medical Technologies)
  56. 8.10.1 GI Supply (Laborie Medical Technologies) Company Information
  57. 8.10.2 GI Supply (Laborie Medical Technologies) Business Overview
  58. 8.10.3 GI Supply (Laborie Medical Technologies) Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GI Supply (Laborie Medical Technologies) Malignant Ascites Treatment Product Portfolio
  60. 8.10.5 GI Supply (Laborie Medical Technologies) Recent Developments
  61. 8.11 CMP Pharma
  62. 8.11.1 CMP Pharma Company Information
  63. 8.11.2 CMP Pharma Business Overview
  64. 8.11.3 CMP Pharma Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 CMP Pharma Malignant Ascites Treatment Product Portfolio
  66. 8.11.5 CMP Pharma Recent Developments
  67. 8.12 Clover Biopharmaceuticals
  68. 8.12.1 Clover Biopharmaceuticals Company Information
  69. 8.12.2 Clover Biopharmaceuticals Business Overview
  70. 8.12.3 Clover Biopharmaceuticals Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Clover Biopharmaceuticals Malignant Ascites Treatment Product Portfolio
  72. 8.12.5 Clover Biopharmaceuticals Recent Developments
  73. 8.13 BioVie
  74. 8.13.1 BioVie Company Information
  75. 8.13.2 BioVie Business Overview
  76. 8.13.3 BioVie Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  77. 8.13.4 BioVie Malignant Ascites Treatment Product Portfolio
  78. 8.13.5 BioVie Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst